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Table of Definitions
Table 1. Terms, Abbreviations and Definitions
Term or Abbreviation
Definition
Artificial Intelligence
Any computer/software or technology
that can perform a task requiring intelligence
and most often those tasks previously
requiring human work
Machine Learning
The science that deals with development of
algorithms capable of propelling a computer
system to learn
Deep Learning
A subset of machine learning the relies on
neural networks to simulate nature learning
and allows for analyzation by computers of
complex problems
FDA
The US Food and Drug Administration; the
primary regulatory and oversight body of the
US Federal Government for the
biopharmaceutical industry
NDA
New Drug Application-the official filing with
the Food and Drug Administration or
regulatory body to gain permission to market
a medication
In Vitro
A research environment outside a living body,
normally for testing compounds
In Vivo
A research environment within a living body,
normally associated with clinical trials and
testing medications and compounds
Cytochrome P450
A supergroup of human enzymes that plays a
major role in the breakdown and metabolism
of many medications
High Throughput Screening
A process used to test high volumes of
chemical compounds for specific use
Label
The official approved instructions for the
proper use of a medication, the indications for
which it is appropriate and the scientific basis
for its use
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Abstract
The challenge of bringing new drugs to market through discovery and development is
nothing short of daunting in the biopharmaceutical industry. The process is very expensive, very
risky and carries a high failure rate, however, it is necessary to sustain the biopharmaceutical
industry in bringing new medications to market. In fact, much of the recent literature supports
the position that the biopharmaceutical industry faces a more difficult task than most industries
in the development of new products, given the escalating cost of research and development, the
high regulatory hurdles, and a declining success rate in the discovery of new drug compounds.
(Lo, 2021) In addition, the expense of drug discovery and development has a direct impact on the
price of medications once they reach the market. Improvements in the drug discovery and
development process, therefore, are critical to the long-term success of the biopharmaceutical
industry and its ability to find new medications to improve the lives of patients. Artificial
Intelligence has long been touted as a route to more efficient, less costly, and more predictable
outcomes in the drug discovery and development process. Yet, despite the promise of this
technology, there has been little evidence to support that drug discovery and development has
become more efficient or less expensive in recent years. In addition, the biopharmaceutical
industry has not fully embraced or embedded AI as a core strength in bringing new drugs to
market, despite its potential to lower costs, time needed, and manpower required to discover new
medicines. This research explores perceived value of AI within the industry as contributing
factor to the relatively low adoption of this technology. The specific focus in this research is the
view that executive biopharmaceutical managers, tasked with the allocation of limited resources,
hold regarding the use, value, and applicability of Artificial Intelligence as a tool within drug
discovery and development.
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Introduction
The biopharmaceutical industry relies on its ability to market new products for patients
living with conditions that range from acute infections to chronic and rare conditions which may
last the course of a patient’s life. The investment of resources to bring medications to market, is a
strategic decision that must be made by each company and may shift over time as revenue and
company position changes within the market. In the case of the biopharmaceutical sector, the
decision to invest in drug discovery and development represents great risk given the cost and
amount of time required to bring new drugs to market, to say nothing of the steep regulatory
environment, and rapidly changing landscape in healthcare. In a comprehensive study conducted
in 2016, the Tufts Center for the Study of Drug Development concluded that on average the cost
to bring a new medication to market was $2.6 dollars and carried a failure rate of 90% for
molecules identified but never making it to the market as a medication. (DiMasi, et.al 2022)

In addition, it takes on average, more than 10 years for the drug discovery and
development process to move from identification of a potential compound for medication to a
market-ready medication, approved for use. As if the time and financial considerations were not
sufficient, an additional study by the Center for Medicines Research International (CMRI),
estimates that biopharmaceutical companies have only a 4.9% success rate at bringing new
medications from initial toxicity screening to approval and use in the market, due to the myriad
pitfalls of clinical trial set backs, failure to meet clinical endpoints, toxicity and side effect
profiles a host of other unknown factors, that are often discovered several years into clinical
testing. . (Peck et al. 2015).
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In addition to understanding the pressure this atmosphere places on the
biopharmaceutical industry, another important consideration that should be given to these
challenges is that these costs, time constraints and heavy failure rates play a direct role in the
price that patients ultimately pay for medications. Biopharmaceutical companies, even when
successful at bringing new medications to market under these conditions, have limited time to
recoup the sunk costs of research and development, which is normally tied to the patent life of
the medication, which temporarily prevents the market intrusion of generic competitors, who had
the advantage of not investing the time and resources into the drug discovery process that created
the medication. As the costs of drug discovery and development continues to climb, so too do the
prices of medication, to the degree that these costs must be recovered.

It is not difficult to see then, why the touted potential of artificial intelligence AI, offers
so much promise in its potential ability to streamline the drug discovery and development
process. As AI offers the industry a mechanism for more efficiently, quickly, and accurately
combing through millions of potential new and known chemical compounds to evaluate potential
medical use, the possibility of etching into a 10-year average to bring new drugs to market is a
realistic possibility. Furthermore, the potential of AI platforms to alleviate and compliment the
work of professional researchers with automated search and modeling platforms represents
potential savings of millions of dollars in research and development costs, to say nothing of
increasing the success rate of approvals through more accurate modeling and historical
projections. It is in this setting in context that this research seeks to understand why there is
relatively low adoption of AI in the drug discovery and development process, or why, as many
researchers note, AI is not yet a core strategy element in the biopharmaceutical R&D space.
(Schuhmacher, 2020) By comparison, many other industrial sectors and leading firms have
13
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embraced AI as a core business strategy and perhaps one of the best know is Amazon, a firm
which, by some accounts derives as much as 35% of its revenue from AI platforms. (Morgan,
2018) Recent history has also provided a valuable learning on at least one potential area of AI in
drug discovery, as AI, in the form of deep learning and machine learning was heavily leveraged
to model existing medications to potentially treat the Covid -19 outbreak. The approach that was
used was called drug repurposing in which currently available medications are modeled against
known variables of the illness in question to model the potential benefits, side effects and
efficacy of known medicines. This is one of the primary avenues used to discover medications
such as Remdesivir, used primarily in the treatment of Ebola outbreaks, as a potential treatment
for Covid-19. The introduction of AI allowed sophisticated modeling to bypass the normally
lengthy endeavor of animal and human testing to identify this medication and others, as potential
treatments. This serves to underscore the potential benefits, cost and time savings that may be
offered using artificial intelligence in drug discovery and development. (Mohanty et. al.,2020)

Because the field of AI covers such a large range of technology, definitions and potential
applications, the focus of this research, narrows AI into two specific areas, Deep Learning and
Machine Learning, as these two areas represent most platforms currently used in the setting of
drug discovery and development. There is no consideration given in this research to AI applied
outside the process of drug discovery and development.
This research is built on a literature review and study of three specific areas; first, drug
discovery and development costs, including a process overview, as well as success rates and
trends over time; second, Artificial Intelligence (AI), with specific definitions to indicate use
within the framework of the biopharmaceutical drug discovery and development process, and the
potential value of AI technology to change the process of drug discovery and development; and
14
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third; management views of AI within drug discovery and development including the value
perception in terms of investment of resources. The conceptual framework used to evaluate the
level of adoption of AI into the drug discovery and development process is the Diffusion of
Innovation Theory (DoI). Ultimately, this research is aimed at assessing the impact that
management views on artificial intelligence in the drug discovery and development process, may
have on the level of adoption and integration of this technology into a biopharmaceutical
organization.
To provide an orientation, a brief overview of the approaches most often used to bring
new medications to market or in some cases, create new usage for existing medications, already
in the market is provided below. Though not the only approaches to bringing new medications to
market, the three approaches outlined here represent most of the directional effort in this area.
While the focus of this research will be on drug discovery and development, it is important for
reference to have a baseline understanding of the prevalent methods employed by most
biopharmaceutical companies today.

1. Drug discovery and development: this process is the core of research and
development in which a biopharmaceutical company, or a dedicated science company
discovers a potential new medicinal chemical or a new application for a molecule that
may have beneficial effects as a medicine. The process is very long, taking an average
of 10-12 years to go from identification of the compound to approved medication. In
addition, this process has a very high failure rate, as less than 2% of identified
compounds and molecules will pass testing and become medication. The process
involves several steps from clinical assays on potential chemical compounds to
extensive testing in animals and human subjects as well as extensive regulatory
15
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filings and submissions throughout the process. (Freedman, 2019) Outlined below is
chart which identifies, at a very high level many of the key aspects in the drug
discovery and development process, this will be discussed in greater detail throughout
the research.

2. Acquisition of new drugs-Many biopharmaceutical companies rely on a strategy of
acquiring late-stage drugs developed by other entities or very often, simply acquiring
the entity the owns the intellectual property of the molecule of interest. This strategy
is often seen as less risky than investing in the entire process of research and
development, although, to be clear, this is not without risk, as most compounds are
acquired prior to FDA approval to market the new medication. (Banerjee & Siebert,
2017)

3. Exploitation of Existing drugs and markets-For many biopharmaceutical companies,
the strategy for market share and profitability relies more heavily on maximizing the
efficiency of existing medications, including the introduction of generic medications
within established classes of medication already on the market, seeking expanded
usage approval and new indications for use from the FDA and making monetary
efforts to improve contracts with insurance carriers and distribution networks, to
maximize return on existing portfolios. This approach relies far less on innovation
and more on market activities throughout the lifecycle of a medication. In addition,
although not limited to those biopharmaceutical firms that employ exploitation is a
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core strategy, expanding the approval and use of medications into new regional and
global markets is also a key component for growth and return.

The focus of this research is specific to the approach of drug discovery and development
as core strategy. While most biopharmaceutical companies benefit from a larger market of
approved and effective medications, not all players in this sector have the resources,
competencies, and strategic drive to become heavily invested in drug discovery and development
and this research makes no attempt to distinguish the relative merits of any one strategy for
growth.
For those companies investing in the approach of drug discovery and development, the
commitment of time, resources and risk is significant, and this bears a direct impact on the price
of medications once market approval is achieved, as the initial investment is factored into the
desired return. Given this environment, any opportunity for efficiency, reduction in cost and
technological streamlining is seen as a positive and Artificial Intelligence (AI) has been touted
for many years as a potential money and time saver within the process of drug discovery and
development. Empirically however, AI appears to be still in the very early stages of
implementation within drug discovery and development with outcomes that are not clearly
delineated and understood. This may be for a variety of reasons from the sporadic nature of data
libraries available for AI implementation, to the lack of understanding and acceptance of the
biopharmaceutical sector, which has long relied on traditional scientific discovery models.
(Bender & Cortés-Ciriano, 2021) In this research, the focus is on the relation between the
management and decision-making teams at biopharmaceutical firms view of artificial
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intelligence in drug discovery and how this may be a cause of lagging implementation of this
innovation.
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Research Question
Does management view of the value of artificial intelligence in the process of drug
discovery and development impact the level of AI adoption?
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Conceptual Framework
The framework incorporated for this research is the Diffusion of Innovation Theory. This
theory examines the communication at both the individual and organizational level of
communication regarding an innovation, that can lead to the adoption or diffusion of that
innovation, in this case, artificial intelligence. Diffusion of Innovation or (DOI) Theory, was
developed by E.M. Rogers in 1962, and thus is one of the oldest social science theories. It
originated as a focus in communication to explain how, over time, an idea or product gains
momentum and then spreads, or diffuses through a specific population, organization, or social
system. For this diffusion to take place, the actors in an organization must perceive some value in
adopting the innovation, thus they are motivated to change their behavior in adopting or
diffusing the innovation. The result of this diffusion is that people, in this case, within an
organization, adopt a new idea, behavior, or product, which in the focus of this research, is
artificial intelligence as a value additive for drug discovery and development.
The emphasis of the theory is that diffusion is process of communicating over time,
through multiple platforms such as face-to-face, electronic, and mass corporate communication
within a social system or in this case, commercial organization. It is worth noting that all
communication over time has influence of the diffusion of innovation, however, the theory
focuses largely on two-way communication as opposed to one-way, from a specific source to a
selected audience, so that standard, one-way corporate information is not generally considered
part of the process of diffusion on innovation. (Rogers 1995)
At its core, the Diffusion of Innovations theory lays out five elements that have direct
effect on how well and how quickly an innovation is adopted, in this case, by an organization:
(1) does the innovation have relative advantage over existing methods? (2) are the innovations
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compatible with existing values, experience, and current needs? (3) are the innovations simple to
understand? (4) can the innovations be tried by potential adopters? (5) are the innovations
observable so that potential adopters can see the results for themselves? (Miles, 2012)
Ultimately, as an innovation is diffused successfully through an organization, the result
should be a change in behavior of the actors involved, so that the innovation is so well diffused
and accepted that observable changes in behavior, related to the innovation are evident.
The overlay of the Diffusion of Innovation (DOI) theory is outlined in the hypothesis and model
below. The fourth element in DOI, which deals with the ability of adopters to try the innovation
is not being evaluated in this research, primarily because the implication of simple, linear, and
isolated use of artificial intelligence as a “trial” innovation does not apply itself in the setting of a
biopharmaceutical organization attempting to improve the drug discovery process.
Although it was not implemented in this research, the Technology Acceptance Model
may also be an excellent fit for future research and its approach to measurement is similar in
some respects, as that model focuses on Perceived Usefulness and Perceived Ease of Use as two
factors to be considered. (Holden, 2011)

Research Hypothesis Stated
H1. The perceived advantage of innovation (AI) impacts management view of that innovation.
H2. Innovation fit with the existing values of a firm, will impact management view of the innovation.
H3. The ease of understanding AI will impact management view of the innovation (AI).
H4. Observable results from an innovation (AI) impact management view of the innovation.
H5. Management view of innovation (AI) impacts the innovation level for the firm.
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Hypothesis Model Illustrated
Innovation (AI)
Perceived Advantage

Innovation (AI) Fit w/
Existing Values

Innovation (AI) Ease
of Understanding

Observable Results
from (AI) Innovation

22
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Literature Review
A systematic literature review was conducted using EBSCO, Medline, Google Scholar,
and ProQuest database engines, as well as SEC10-K and 10-Q reports to research costs
associated with drug development and discovery, time needed to bring new medications from
discovery to market, the application and current use of artificial intelligence in drug discovery
and management viewpoints on the value of artificial intelligence in drug discovery.
This research was conducted to allow a more detailed understanding of several key
elements that factor into the drug discovery and development process, its shortcomings and at
least one potential avenue for managers to improve the odds of more successfully bring new
medications to market, namely the implementation of artificial intelligence into the process. The
background literature review focused on the current problem and setting, an overview of the drug
development and discovery process, the dollar costs of bring new medication to market, as well
as the length of time needed to bring new medications forward and the regulatory environment in
which biopharmaceutical firms operate. These are not the only areas worth research in
understanding the complexities of the drug discovery and development process however, these
are the focus areas that influence this research.
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Background and Problem Setting
Bringing new medications to market is both the lifeblood of the biopharmaceutical
industry and a pivotal piece of ever-improving healthcare and the treatment of disease.
Biopharmaceutical companies involved and invested in the research and development of new
medications must make an ongoing strategic decision about the level of resource investment to
focus on a highly risky venture, namely, the discovery and development of new medications to
bring to market. This decision must balance the need to maintain a level of operational profit,
that allows for research and development investment, with a high-risk investment strategy that
carries long term potential but has numerous and often unpredictable pitfalls throughout the
entire process. Despite technological advances as well as experiential knowledge of the drug
discovery process, proportionally fewer new drugs have come to market in recent years, despite
an increased allocation of resources. In fact, one empirical study showed that despite almost
doubling of the aggregate research and development (R&D) budget of the pharmaceutical
industry from $68 billion in 2002 to $127 billion in 2010, it is difficult to discern any appreciable
impact on the number of new drugs approved during the corresponding time. (Fernandez et al.,
2012) The phenomenon of this inefficiency has in fact, become so well known that it is now
often termed “Eroom’s Law,” which is the reverse in spelling and opposite in meaning of
Moore’s Law, an economic principle that predicts increased output will be gained from
experience. (Lo, 2019) In the case of drug discovery, experience seems to be leading to lower
numbers in terms of output and at much higher cost than traditionally observed. This fact has not
escaped the leadership of the top biopharmaceutical companies and this is one area in which
there is great potential in the use of artificial intelligence.
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Exerting additional pressure on this background, the high price of medication and of
healthcare in general is a well debated topic among consumers, legislators, patient advocates and
political pundits over the last 10 or more years. There has been a great deal of discussion,
political action, and enacted regulation passed or considered to curb the price that consumers, or
patients, pay for medication. In addition, the topic of medication prices is a very heated debate,
often consisting of very little fact or knowledge of what goes into the pricing of a medication. As
evidence of this lack of knowledge and fact, one critical element in the cost of medication that is
rarely considered, at least at the level of public discourse, is that of the cost and difficulty of
discovery and development of new medications. This lack of education and understanding adds
to the pressure placed on biopharmaceutical research companies to explore new methods and
approaches for curbing cost at every stage of production and discovery dealing with medication.
To illustrate more concisely the difficulty of bringing new medications to market, it is of
note that recent research reveals that of more than 10,000 potential new medications in
development each year, only one makes it to the market as a new medication. (Pennings &
Serono, 2011) Another study, which looked at investigational compounds being considered for
new medication research globally by the 50 largest biopharmaceutical manufacturers, saw only a
16% approval success rate for use in the United States. (Dimasi, 2001) These low approval and
pass rates are due to a combination of factors which include, a high failure rate among potential
chemical compounds, unfavorable toxicity profile for potential new compounds, the cost of
bringing new medications through the discovery and development process, the steep regulatory
requirements for passing each stage of development and the length of time that this process takes
and myriad additional considerations. As table 2 outlines below, the number of new drugs
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coming to market has remained relatively steady and relatively low despite the increased
expenditure on research and development.
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Table 2. Number of New Drugs Granted Marketing Authority in the U.S. 1993-2010
Year
1993
1994
1995
1996
1997
1998
1999
2000
2001

27

Total Drugs
Year
Total Drugs
70
2002
78
62
2003
72
82
2004
119
131
2005
8
121
2006
101
90
2007
78
83
2008
89
98
2009
90
66
2010
93
(Source: Biopharm Insight-Approved Drug Database)
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The Drug Discovery and Development Process
To better understand the process and the risks faced by biopharmaceutical managers, a
brief overview of the generally accepted model of testing new potential compounds on their way
to becoming viable medications and approved for use by consumers is outlined here. As outlined
below, most drug development and discovery can be broken into four broad categories: research
and development, pre-clinical, clinical, and review and approval. This process is often
represented in phases as well, with Phase I being pre-clinical, Phase II being clinical and small
safety trials with humans and Phase III consisting of larger human trials for efficacy and safety
and Phase IV activities taking place after the drug has been approved for use. This process is
outlined in Figure 2 below.
It is not necessary to have an in-depth understanding to digest this research, however, a
cursory knowledge of the process, as outlined below should lend understanding for most readers.
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Figure 2. Drug Discovery and Development Timeline

(Source: Innoplexus.com)

29

Management Perceptions of the Value of AI in Drug Discovery and Development

In the research and development stage, the focus of the biopharmaceutical company or
research company is primarily to identify viable candidates for testing as medication in human
use, normally through the process of compound screening, also known as high-throughput
screening which boils down to literally combing through tens of thousands of potential
molecules and compounds to find those which offer the possibility of efficacy for a given disease
or illness and a relatively lower potential toxicity for human subjects. Through exhaustive
chemical analysis and comparison to similar compounds with known safety profiles, this portion
of drug discovery and development often takes several years and represents a very high dollar
cost. The goal is to provide a reasonable and scientific method to test potential chemical
compounds in vitro to identify desirable targets that may exhibit desired biological action, in
other words, to identify chemical compounds which show promise as potential medicines.
(Pereira et. al. 2022) Traditionally the analysis and testing done in the research and development
phase has been conducted by highly trained scientific personnel, chemists, and other professional
researchers. This portion of the process may take several years and experience very high failure
rates in terms of compounds suitable to continue in the clinical research.
The preclinical phase or Phase II normally involves In Vitro and In Vivo studies of the
potential compound to determine potential efficacy against a target set of disease or illness. The
goal is to progress to a level that justifies testing in non-human mammals. This portion of the
process takes at least one full year for most compounds and is very expensive, especially if
mammalian trials are undertaken.
The clinical or Phase III portion of the drug discovery and development process involves
larger scale human trials in which the true efficacy and specific parameters, such as prevalent
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side effects, rates of absorption and interaction with other drugs are tested. This phase of testing
often takes between 4 and 7 years to complete.
The final phase, assuming success in everything that lead up to this stage, is to obtain
regulatory approval, which in the United States, comes primarily from the Food and Drug
Administration (@US_FDA). While all relevant data, clinical trials and testing have been
successfully completed by this point, this stage of the drug discovery and development process
may still take upwards of two years, depending on the regulatory schedule, requests for
additional information, examination of clinical proofs and the general workload, or backlog at
the FDA and other regulatory agencies. A more detailed outline of the individual stages and
related activities is provided in Figure 3 below.
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Figure 3

Understanding the Drug Discovery Process

(Figure 2 Source: CompoundChem.com, 2021)
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Dollar Costs Examined
First, it is important to understand the estimations of the actual dollar cost of bringing a
new medication to market vary dramatically, depending on the source of the research and what is
factored into the cost analysis. For example, differing research may include different factors of
pre-clinical costs and regulatory filings, while other research may only count the pre-clinical
costs. Research figures since 2000 range from $165 Million to $4.5 Billion and everywhere in
between. According to a 2016 study conducted by the Tufts Center for the Study of Drug
Development (CSDD) for example, the average price to bring a new medication to market was
$2.6 Billion. (Subramanian, 2020)
Critics would argue that $2.6 Billion is too high and considers too many elements in the
calculation, as well as alleging that Tufts has a very close relationship with the
biopharmaceutical industry which may bias the figures. On the other end of the spectrum is the
research of Vinay Prasad, MD et. al who conducted a study to follow a single drug through
development and yielding reported costs of $165 Million. This research is also the subject of
criticism claiming a downward bias which inaccurately represented the costs by limiting the
factors of development that were examined, among other things. (Prasad et. al, 2017). The
primary point is that there is no established objective method for consistently measuring the
same factors across all research and therefore, this research seeks to understand a widely
acknowledged range of costs associated with drug discovery and development. Likewise, the
literature shows that depending on what time lines and elements are considered within the
definition of drug discovery and development the figures can shift greatly, often by hundreds of
millions of dollars. (Schlander et al., 2021)
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When taken in aggregate, almost all studies referenced in this research placed the cost of
drug discovery and development in a range between $1Billion and $2 Billion to complete the
discovery and development process and bring a new medication to patients in the market and this
does seem a reasonable basis on which to proceed. (Lou & Wu, 2021)
These costs, averaging between $1-2 Billion from discovery to market, represents an
increase of more than 14 times the cost of the same discovery and development process in the
1970s and this cost has increased an additional 2.6 times between 2010 and 2020. (Takebe et al.,
2018) Again this is a daunting trend for biopharmaceutical manufacturers to consider when
investing in the development of new medications. To put this in more historical context, the cost
of developing new drugs and bringing them to market has doubled approximately every nine
years since the 1950’s, and in the current environment, there is no sign that this trend, or at least,
continued steep escalations in the cost of drug discovery and development will be reduced by
any significant figure soon. (JW et al.) This represents not only a challenge for the
biopharmaceutical industry but also for society, given that drug discovery and development costs
are one direct factor in the consumer price of medications.
In this high-risk, high-cost venture, even financially successful biopharmaceutical
companies must balance the desire to invest in new medication development with the realistic
and more immediate need to maintain a healthy profit in other segments of their business. This is
one reason that biopharmaceutical companies are ripe for investment and adoption of new
innovations, including artificial intelligence in their search for more cost effective and efficient
methods of bringing new drugs to market.
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It is important also to keep in mind that while hundreds of millions of dollars per year are
spent on drug development and discovery, the number of New Drug Applications (NDA) which
clear all regulatory hurdles and gain approval for marketing by the FDA is not a large number.
Outlined in Table 1 above is a year-by-year total of the new drugs approved for marketing in the
US between 1993 and 2010. (Banerjee & Siebert, 2017) Again, these figures play a significant
role in the availability and cost of medication and highlight the apparent phenomenon of
spending ever increasing amounts of resources and seeing fewer results over time.
An additional consideration is that cost cannot be thought of in strict, current dollar terms
alone. Like most economic and investment strategies, a large opportunity cost is represented by
the expenditure of such an expensive venture, both in terms of dollars and resources. The
biopharmaceutical company and its managers must also contend with the need to predict general
economic conditions of the market into which a new drug may be entering, more than a decade
into the future. This need has created the expenditure of millions of dollars by most
biopharmaceutical companies on prediction modeling, analysis, and big data purchases to model
the markets at a future point. As medications have become more expensive at the consumer level
and the trend of insurance companies has been to pass the increased prices along to the
consumer, or patient in the case of biopharmaceuticals, the market dynamics and ability to
receive favorable reimbursement through various healthcare systems may be as important in
calculating cost as that of the expenditures to develop and bring new drugs to market.
One additional consideration on cost is that, in many markets, especially the U.S.,
biopharmaceutical companies must provide deep discounts to payers, more commonly known as
insurance companies, to receive favorable access for the patients represented by those companies
and these discounts play a significant role in the profitability as well as net price set for many
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products. (Smith et al.2019) In addition, the introduction of biosimilar and generic medications,
the potential loss of patent exclusivity and myriad other market conditions are all factors of price
and more important, factors which must be considered as strategic imperatives when deciding the
investment level and ultimately the fate of many potential new drug compounds in discovery.
Finally, these expenditures are made more complex by the fact that patent durations on
branded medications are relatively short in industrial terms which exerts additional pressure on
biopharmaceutical companies to price medications for a short-term market position. In some
cases, the patent life of a medication can often begin before the medication is even available to
the public for use. (Pandey, 2019)
Regardless of methodology in calculating the cost of new drug discovery and
development, what is verified across voluminous research is that the cost is very high and does
play a factor in the cost of medications.
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Failure Rates: A Closer Look
While it may seem a detail too far in terms of understanding the process, the high failure
rates within the drug discovery and development process are a key driver of dollar and resource
costs and a particular area of interest in terms of new technologies, such as artificial intelligence,
that promise greater efficiency and success and therefore, a closer understanding is warranted in
this discussion.
Failure rates of potential new compounds in the biopharmaceutical discovery and
development process, are some of the highest in any modern industry, reaching as high as ninety
percent in the first phases of research on new compounds. (Freedman, 2019) In other words,
ninety percent of identified new potential compounds never complete the first three phases of
testing. One reason for this is that proving efficacy against a disease at this stage of development
is virtually impossible beyond a strictly theoretical assumption. One reason for this is the
complexity of the human being as the end customer, requiring potential toxicity and side effects
of a new medication to be studied as diligently as any potential benefit of a new compound. The
human production of cytochrome P450, a family of critical enzymes that help humans to break
down chemicals in the body, thus preventing toxicity, is one example of the complexity involved
in evaluating early stage potential chemical compounds being evaluated for medicinal use, as the
effects of the experimental medication must be modeled against the potential reaction to this
system in potential patients to determine if and how the drug may be broken down and used by
the body or if this family of enzymes will inhibit the viability of the compound. This cytochrome
P450 family of enzymes is critical in assessing potential toxicity and safety of potential
compounds and requires very complex, large data modeling to reasonably gauge the risk of these
potential side effects to decide if a drug candidate should continue to receive funding, time, and
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resources to bring it forward in the development process. Accurately predicting these interactions
may well determine the viability of a compound for use as a medication, decades before human
testing of the compound is even possible, again underlying the complexity and risk of drug
discovery as a business proposition. Indeed, much research points to the fact that a large
percentage of drugs on the market today were studied because the pathway that they used
through the cytochrome P450 family of enzymes was already known from other compounds,
thus promising a better chance of a favorable side effect profile. (Guengerich, 2004)
While science and technology are providing new and more efficient ways to screen and
test potential new medications in virtually every area of healthcare, the cost of implementing this
technology and bringing new medications to market for patients continues to rise, prohibiting
many organizations from entering the drug discovery and development pipeline. In addition, like
all new and emerging technologies, the return on investment is often slow to become apparent, if
it becomes apparent at all. In fact, it is elucidated in research that although technology is
promising, to date, no AI-discovered compounds have yet reached the animal testing phase of
drug development, to say nothing of human testing. (Freedman, 2020)
Nonetheless, technology is being employed in many settings to gain an advantage where
possible in the development process. A current example is the growing use of artificial
intelligence (AI) in drug discovery, which is being applied in a variety of ways in hope of
shortening the lifecycle from potential molecule to medication. Along with the hope of a more
efficient drug discovery and development lifecycle, is the aspiration to lower the cost of
development of potential new compounds. To this end, we see the introduction of Artificial
Intelligence (AI), primarily in the form of advanced machine learning and deep learning. One
example for illustration, is the use of machine learning to search for the so called “open targets”
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in which computer systems screen and study pre-clinical compounds by the thousands that once
would have required manual testing by highly qualified scientific personnel. (Borisa et al., 2020)
This type of AI-based technology and many others based on AI, deep learning and a host of
computer-aided advances offer the possibility of lower cost and shorter timeframe from
molecular discovery to development and ultimately the availability of new medications. To date,
however, the cost of the discovery and development process continues to increase and the
average time from discovery to availability has not changed, on average for most categories of
new drug discovery. (Wong et al., 2018)
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Drug Discovery and Development Time Examined
If the cost alone is a staggering consideration when looking at the drug development and
discovery process, recent studies provide an equally daunting picture of the amount of time
needed to complete the process. The exact time needed to complete the drug discovery and
development process is subject to many factors, such as the therapeutic class of medication, the
novel nature of the potential medication, the passage rate through each stage of the process
experienced by a particular drug candidate and many other factors. What is however, agreed
upon across the empirical research is that the process is quite long, averaging 12-15 years from
the identification of a potential drug compound to its approval for use as a medication. (Hughes
et al., 2011) This time horizon itself may present a hurdle too high for some biopharmaceutical
companies, as it multiplies the complexity and risk by adding a requirement that forecasting
market conditions more than a decade ahead becomes a necessary element in considering the
investment to undertake drug discovery and development.
The length of time needed to successfully bring a new medication to market plays a direct
role in the economic forecast in fact, which influenced companies to participate in the process
and may contribute as well to the relatively low numbers of New Drug Applications (NDA)
coming through the pipeline in recent years. It is certainly understandable that many
biopharmaceuticals and private research companies are simply not in the economic or logistic
position to invest in a process which takes on average 15 years from conception to drug
approval. (Pennings & Serono, 2011)
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The Regulatory Environment
The regulatory environment into which biopharmaceutical companies bring new
medications from discovery to market is itself an expensive and complex ecosystem, which
requires time, money, and significant resources to navigate. In general, regardless of geographic
location, regulatory agencies must provide permission to market a medication, before it may
legally be sold or prescribed, regardless of the status of the clinical trial results and scientific
evidence.
One example is the process, in the United States, of obtaining proper labeling, which in
essence is the official license to market a medication as a treatment of a particular disease or
illness. The process of obtaining a label, which dictates specifics on the way the medication may
be used to treat illness, falls under the purview of the Food and Drug Administration (FDA).
To obtain a marketing label, the biopharmaceutical company must submit all clinical
findings, trial results, side effect profiles and all other relevant information to the FDA for a
review and determination of how the medication may be marketed. This process is outlined
below as an example of similar processes that take place globally to allow the marketing and
proper use of medications and to illustrate further the length of time, commitment of resources
and investments that must be made to bring new medications to market.

If a biopharmaceutical or drug manufacturer discovers evidence in early testing or
preclinical and clinical research that a potential drug is safe and effective for its intended use, the
company would generally file an application to market, or sell the drug, known as a New Drug
Application (NDA). The FDA review team thoroughly examines all submitted data on the drug
and decides to approve or not to approve it. A New Drug Application (NDA) tells the complete
clinical story of a potential drug, including all currently known applications, side effects and
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potential uses. Its purpose is to demonstrate that a drug is safe and effective for its intended use
in the population studied.

As mentioned, the biopharmaceutical manufacturer must include reports on all studies, data,
and analyses. In addition, the biopharmaceutical manufacturer must also provide the proposed
labeling, which is the proposed dosage, intended population, safety updates, drug abuse
information, patent or intellectual property information, as well as any data from studies that may
have been conducted outside the United States, along with institutional review board compliance
as applicable and information on the intended or potential directions for use.

Once the FDA receives an NDA, the review team decides if it is complete and contains all
the information needed to proceed with review. If the application is not viewed as complete, the
review team can refuse to file the NDA. If the application is complete in the view of the board,
the review team has 6 to 10 months to decide on whether to approve the drug, although the
process may be much longer than this depending on the backlog at the FDA. During the review,
several steps take place including inspection of the clinical study sites, manufacturing facilities,
suppliers and so on. In addition, each section of the submission is reviewed by subject matter
experts, so that statisticians may review clinical outcomes data and medical officers may be
reviewing the pharmacology and clinical impact of the proposed medication.

In cases where FDA and its review board determine that a drug has demonstrated itself to be
safe and effective for its intended use, it is then necessary to work with the biopharmaceutifcal
company or applicant to develop and refine prescribing information, based on clinical trial
results, which is more commonly known as “labeling.” Labeling, or the specific instructions for
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taking a medication within a specified patient population, is designed accurately and objectively
describes the basis for approval and how best to use the drug. (FDA Drug Review, 2022)

Similar processes take place in most countries where prescription medicine is available and
this is combined with regulatory filings and oversight on all marketing efforts, collection, and
management of medical information about the medication post marketing, label updates,
manufacturing changes etc. The overarching theme is that the regulatory hurdles, expenses, and
resource dedication needed to bring new drugs to market can be significant.

When the regulatory difficulties are combined with the cost of drug development and
discovery and the time needed to the complete the process and bring a new medicine to market,
any advantage or efficiency that may be gained is of critical importance and gaining efficiency is
has been the core potential of artificial intelligence (AI) in the drug discovery and development
process.

43

Management Perceptions of the Value of AI in Drug Discovery and Development

The Decision Faced by Biopharmaceutical Strategy Leaders
Even given the vast amounts of resources needed to complete the drug discovery process,
the decision to invest in new drug discovery and development may seem straightforward to most
consumers, patients and even legislators who follow the biopharmaceutical industry, however,
even in the case of an organization committed heavily to new drug development and discovery,
the decision to invest in such a high-risk area, with virtually no guaranteed return, is one of the
most difficult decisions to be made in the ultimate financial fate of a biopharmaceutical
company. It is established in research literature that due a combination of high clinical failure
rates, high costs, steep regulatory environment, and the extensive length of time needed for the
drug discovery and development process, only 1 in 10,000 thousand potential clinical
compounds identified make it to market as an available medicine, approved for use by patients.
(Pennings & Serono, 2011) The high failure rate is not due simply to a lack of efficacy in a
potential new medical compound, although this certainly accounts for a percentage of failures;
the biopharmaceutical firm must also consider the safety profile of the potential new medication
and the economic profile at each stage of development. For example, a compound may show
potential in terms of efficacy to treat a particular illness but have such a toxic side effect profile
that continuing trials is not scientifically viable. Likewise, a novel potential new compound may
pass muster on both the clinical and safety fronts but may still represent such a small potential
treatment group, that spending hundreds of millions of resource dollars and more than a decade
in development is not economically warranted. It is understandable that biopharmaceutical
managers in this environment then, would be open to an innovation that promises high success
rates, lower costs, and greater efficiency, such as the implementation of artificial intelligence.
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Artificial Intelligence and its Role in Drug Discovery and Development
First, we must ground the research with an understanding of artificial intelligence and
how we mean to apply this term in the context of drug discovery and development. We can
broadly describe artificial intelligence as any network, computer, or software-based system with
the ability to interpret data, learn from that data, and use that data and learning to achieve
specific goals and tasks through adaptation. (Haenlein & Kaplan, 2019) In addition, in the case
of biopharmaceutical companies, we are including in our definition, that artificial intelligence is
replacing the human laborer in specific areas, all related to drug discovery and development.
While broad, this definition is appropriate as a starting point for the use of artificial intelligence
in the world of biopharmaceutical research and development. At some level, albeit limited, the
biopharmaceutical industry has been using artificial intelligence since around 2000, primarily in
the area of drug discovery and focused traditionally on the organization and review of large data
sets. (Schuhmacher et al.) Artificial intelligence, in all its forms represents potential across many
areas within the biopharmaceutical space, and as one biopharmaceutical executive in the research
survey for this project responded, “I could imagine that the systematic use of AI tools within the
R&D process could lead to moderate savings in time / effort / time to market - or at least
contribute to a slower growth in these metrics. What we do is still research and many things we
care about cannot be predicted - but those that can, should be. This could open the door to new
treatments for diseases that are currently commercially unattractive (orphan diseases).”

While the potential for AI is very broad in the biopharmaceutical space, as outlined in figure 4
below, the focus of this research is in two specific subtypes of AI: machine learning and deep
learning.
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Figure 4: Artificial Intelligence-Potential Use in Drug Discovery
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Machine Learning
It should be stated at the outset that this research does not attempt an in-depth explanation
of the technical parameters or capabilities of Machine Learning. Machine learning is a type of
artificial intelligence which uses pattern recognition algorithms, normally in very large data sets,
to model potential outcomes. Put another way, machine learning is a subdiscipline of artificial
intelligence, that uses algorithms and complex statistical models to allow computer systems to
perform tasks without being specifically programed to perform that task. While there are many
different disciplines with machine learning, some of the main approaches in machine learning are
supervised and unsupervised learning, deep learning, and dimensionality reduction, which are
summarized in definition in Table 2 below. Generally, artificial intelligence includes any and all
methods for enabling computers to display human-like understanding and intelligence, however,
machine learning is focused specifically on developing complex algorithms to learn from data
without human reprogramming at every iteration and this application is the focus of this study as
it is highly applicable in the process of drug discovery and development.
While many applications of Machine Learning offer benefit in drug discovery and
development, such as dimension reduction, outcome modeling and organizing large amounts of
data, perhaps the most prevalent use of machine learning today is in High Throughput Screening
(HTS). This is a process in which vast libraries of biological chemicals are evaluated to identify
potential new drug compounds. Traditionally, combing through these libraries was a task left to
human scientists to perform, through assay and chemical experiments. In addition to testing, the
scientist and professional teams were asked to simultaneously evaluate the potential regulatory
and clinical risks associated with potential new compounds, based on historic new drug filings
and data from previous clinical trials. (Fox et al., 2006) The implementation of machine learning
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has not only allowed for the replacement of highly trained scientists from this monotonous task,
but it adds the capability for biopharmaceutical companies to see conditional prediction models
of success including dozens of factors such as previous clinical trial design, likelihood of drug
approval, potential new drug characteristics, and a host of other input factors.
It is not difficult to see then, why Machine Learning (ML) capabilities are gaining
prominence in the pharmaceutical industry’s attempt to improve and automate the drug discovery
and development process. Machine Learning offers the potential ability to accelerate and
automate the analysis of ever larger sets of data as they become available through repositories
such as PubChem, DrugBank, ZINC etc. (Carracedo-Reboredo, 2021)
While the use of machine learning is not yet standard in the biopharmaceutical industry,
its growth should allow for a greater degree of confidence in new molecule development, to say
nothing of the added efficiency and breadth of examination through the vast libraries of chemical
compounds. (Lo, 2019)
Several concepts at the core of machine learning in this setting have been identified and
defined in table 3, below which represent only some of the critical areas which may be served by
implementing machine learning.
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Table 3: Machine Learning Concepts Defined
Concepts
Supervised,
unsupervised, and
semi-supervised
learning
Classification and
regression
Ensemble learning

Deep learning

Dimensionality
reduction

Federated learning

Definition
Supervised learning predicts labels or classes on future data based on
past data that includes labels/classes. Unsupervised learning identifies
structure, usually clusters, among unlabeled data. Semi-supervised
learning first performs unsupervised learning, and humans label
structures found from unsupervised learning.
Both are supervised learning methods. Classification predicts discreet
categories such as normal versus diseased while regression predicts
real-valued outputs such as response to therapy.
Ensemble methods build many models and use the average of all
models to produce predictions. Common ensemble approaches include
random forests, gradient-boosting, and stacking/meta-ensembles.
Multi-layer artificial neural networks that can learn complex nonlinear functions. Very useful for unstructured data such as images,
speech, or text but typically do not provide insights into the aspects
of the data that are driving the functions.
Reduces the number of attributes or features of a dataset by selecting
important features or combining features to capture variance in a
dataset. Often used to improve performance of machine learning
models and to aid visualization.
Approaches for incrementally learning from data distributed in multiple
locations and which cannot be combined into a single dataset.
Federated learning is useful when data are in multiple clinical systems
or when learning from sensitive personal data.

(Source: Goecks, 2021How Machine Learning Will Transform Biomedicine)
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Like many applications of artificial intelligence, machine learning offers great potential
to improve the process, cost, reliability and viability of the drug discovery and development
process. Perhaps the ability comb through and validate millions upon millions of potential
chemical compounds is one of the most profound, but it certainly is not the limit of machine
learning applications in this channel.

Figure 5 below provides a simplified graphic of the feedback loop that machine learning
applied to chemical compound libraries can assist with.
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Figure 5.

Machine Learning for Chemical Discovery

(Figure 5 Source: Tkatchenko, 2020 Machine Learning for Chemical Discovery)
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Deep Learning
I will iterate again here that this research is not an attempt to explain or diagram in detail
the complex subject of artificial intelligence (AI) or deep learning (DL), but rather to provide a
context specific overview of the application of this branch of AI within the drug discovery and
development process. Voluminous and very high-quality research has been published on the
technical aspects of deep learning, and my intention in this research is only to put this field into
relative context.

Deep learning (DL) is a branch of artificial intelligence and a sub-branch of machine
learning (Baptista et al.), and essentially a complex algorithm that allows computers, networks
and software systems to learn from experience, thus eliminating the need for direct programming
by human beings at every new task assignment. In deep learning, the computational system
builds upon knowledge of simple concepts and concept hierarchy to take on more complex
concepts over time. Since the conceptual learning is built on a well of concepts that increase in
complexity with experience, the term deep learning is applied as the layers of conceptual
learning are presumably deep. Thus, at its most broad definition, deep learning refers to the
system’s ability to acquire knowledge on its own and extract patterns from raw rather than
programmed data. (Goodfellow et al., 2016) One advantage of deep learning algorithms then, is
that high-level features are gleaned from incremental and automatic learning, rather than having
a system that depends on domain expertise. (Piroozmand et al., 2020)

Several factors and conditions have brought deep learning into the forefront of drug
discovery and development along with many other industrial and commercial sectors in the last
several years. Among the critical success factors for the growing use of deep learning (DL) is the
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growth and availability of data sets in the public domain; the advances in speed and capacity in
computational hardware; the propagation of libraries of data, and software platforms and opensource sharing of information both inside and outside of computer science circles across the
globe. (Schroedl, 2019) This is an important consideration in the process of drug discovery and
development since screening potential chemical compounds, ultimately for use as new
medicines, is one of the most costly and slow-moving portions of the drug discovery process. In
addition, the sheer volume of potential compounds to screen is difficult to comprehend for most
clinical researchers, at an estimated order of 1060 potential compounds of which, only a small
fraction have been studied or assessed as potential medicinal compounds or, put another way,
there are billions of potential chemical compounds to be assayed, tested, and modeled against
desired outcomes across a host of diseases, thus making the innovation of efficiency through AI
critical to the drug discovery and development process. (Irwin et al., 2017)

More specific to the process of drug discovery and development, deep learning (DL) is
being used to comb through and analyze very large data sets of chemical compound properties
generated by high throughput screening (Fox et al.), a process through which thousands to
millions of samples are tested for biological activity at the organism, cellular, pathway, or
molecular level with the goal of identifying desirable bioactivity and molecular properties sought
in targeting treatments for a particular disease. (MS Attene-Ramos, 2022) Deep learning is being
used to add efficiency to a process that has traditionally been manual and costly by comparing
known libraries of chemical, biological, and topological properties of potential compounds to
find the most promising drug candidates more quickly and at a lower cost.
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At the core of deep learning (DL) is the use of neural networks (NNs) and it is in these
networks that we see most of the application in the process of drug discovery and
development. Neural networks are the heart of deep learning algorithms. These networks and
algorithms are comprised of node layers, which are simply any physical device that can p
process, collect or interpret data and they are generally broken into an input layer, one or more
hidden layers, and an output layer. Each node or layer, connects to another and has an assigned
importance or weight, often called a threshold. If the output of any individual node is above the
specified threshold value, that node is activated, or sent to the next layer of the network for more
complex analysis and testing, so that only important and relevant findings are being passed to
the next layer in the system. (Education, I.C., 2020)

To date the primary types of deep learning algorithms used have can be broken into three
types of neural networks: Deep neural networks (DNNs); Convolutional neural networks (CNNs)
and Recurrent neural networks (RNNs). Deep neural networks (DNNs) as the name implies, are
networks capable of complex mathematical models capable of analyzing large data sets that may
or may not be linear in their relation. The networks have more than one layer, which both allows
them to look at more complex data and lends itself to explanation of the name, deep. These deep
neural networks can look for potential sought after biological interactions from chemical libraries
and can model potential reaction and efficacy to both known and unknown chemical compounds.
(Baptista et al., 2021) These Deep neural networks (DNNs) have already been used to estimate
drug response in cancer cell lines, among other disease areas and continue to be used to analyze
very large data libraries for potential positive biological interactions. (Preuer et al., 2018)
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Convolutional neural networks (CNNs) represent another advanced type of deep learning
(DL) network which, as the name implies, use convolutions in some of their layers or analysis,
usually in the initial layers of the network. Two-dimensional CNNs are particularly well suited to
handle input data from a grid, such as those used in multidimensional arrays. This characteristic
makes CNNs useful for drug response prediction, if the input data is represented in this format,
which is normally embraced by using compound images as input. (Cortés-Ciriano & Bender,
2019) One-dimensional CNNs are more appropriate for data in the form of sequences, such as
compound Simplified Molecular-Input Line-Entry System (SMILES) strings.

Recurrent neural networks (RNNs) are another distinct set of neural networks, known
primarily for use of sequential data and data that appears in a time series. These deep learning
algorithms are often used for problems that are ordinal or temporal in nature, for example,
language translation, natural language processing, speech recognition, and image captioning; the
most popular applications in the modern era of this technology are apparent in applications such
as Siri and Google Translate, which are heavily used by consumers today. Similar to
convolutional neural networks (CNNs), recurrent neural networks make use of training data to
learn and evolve in the task they are assigned. These networks and algorithms are distinguished
by their ability to use memory or learn as they process information from prior inputs and data
analysis to influence the direction of current input and output. While traditional deep neural
networks treat input and output data as static and dependent, these advanced networks assume
that inputs and outputs are independent of each other, the output of recurrent neural networks
depend on the prior elements within the sequence, in other words, the thinking and application of
outputs evolves as the system learns, this architecture is particularly useful when trying to predict
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the effect that a chemical compound may have on a particular disease or ailment. (LeCun et.al,
2015)
In this way, Deep Learning networks offer potential to bring speed, accuracy, and an
ability to comb vast data libraries not previously realistic to find potential new medications.
Again, the more intriguing element is the limited adoption and implementation of Deep Learning
by the biopharmaceutical industry to date.
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Literature Gap
Prevalent literature was available in all categories for this research except for literature on
the management viewpoint of artificial intelligence or the value it adds to the drug discovery and
development process. There are numerous quotes from biopharmaceutical leaders in trade and
congress publications on the potential application and advances from artificial intelligence,
however, a gap is present in empirical and peer-reviewed research specific to how managers in
this sector view these technological advances and their potential. As this research did not include
trade journal publication, congress proceedings etc., the quotes and opinions of leaders captured
in this type of literature was not included.
To offset this gap, this research includes a survey of biopharmaceutical managers to
capture their viewpoint on the value and use of artificial intelligence in drug discovery and
development.
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Methodology
A systematic literature search was performed using ProQuest, EBSCO, and Medline to
find peer-reviewed empirical studies and research, as well as biopharmaceutical company
reports, SEC 10K and 10Q filings, FDA published data and open-source information. The
literature review was built on keyword drivers including:
•

AI in drug discovery

•

Drug discovery and development process

•

Cost of drug discovery and development

•

Management view of artificial intelligence-pharmaceutical

•

Diffusion of Innovation conceptual framework-application

Emphasis was placed on literature published in 2010 or after as the relevance of the
technology being analyzed and available literature becomes more prevalent and targeted in this
period, although exceptional literature and research from periods before this were selectively
used, for example in the Diffusion of Innovation theory. Focus was given to peer-reviewed
academic journals and research that resulted from conference and congress presentations was
discarded, as well as trade publications and publications that may have conflicts of interest due to
sponsorship or author relationships with the issue being researched. There was no restriction with
respect to the therapeutic area treated by any biopharmaceutical firm or the size of the firm in the
market. Research was broken into three broad categories; the cost of drug discovery and
development; the process of drug discovery and development; artificial intelligence and its role
in the process of drug discovery and development. In addition, complementary research on the
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Diffusion of Innovation framework was performed to provide an informed background on the
conceptual framework for this research.
In addition to literature research and review, a quantitate survey instrument was
distributed to more than 125 biopharmaceutical company managers, academic experts in AI and
clinical experts in drug discovery and development to garner insights and modeling into the
perceived value of AI in drug discovery and its possible impact on innovation adoption levels by
biopharmaceutical firms. The recipients were selected and contacted based upon their working
title and area of expertise within the biopharmaceutical space. Typical areas of responsibility
included but were not limited to; Research and Development; Operational Leadership; Early
Molecule and Asset Development; Scientific Data and Translational Data and Executive
Leadership. All respondents operated at the director level or higher within the organization to
ensure that directional leadership and responsibility was captured through the survey.
The online survey instrument, which consists of 25 closed questions, based either on a
Likert scale or simple yes/no responses was administered through Qualtrics and distributed to
125 management executives in the biopharmaceutical industry. This survey was designed to
collect input aligned with the hypothesis presented by the Diffusion of Innovation framework for
this research and the variables proposed in the model for this research. In this way, the unit of
measure of the study is individual responses, aggregated to the firm level. The instrument was
primarily a quantitative capture of proxy questions used to represent the independent and
dependent variables proposed in this research and detailed descriptions of the survey instrument
and its alignment to research variables is examined the analysis section of this research. Three
open-ended questions were also asked through the survey instrument to gather more in-depth
understanding of the value of artificial intelligence in drug discovery, as seen by
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biopharmaceutical managers. The complete list of questions within the survey instrument, in the
order and appearance seen by respondents is provided in appendix A.
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Sampling
A quantitative survey questionnaire was distributed to 125 biopharmaceutical executives
with experience in drug discovery and development to assess their value perceptions of artificial
intelligence in the process of drug discovery and development. The survey instrument was active
from February 1, 2022, through March 31st, 2022. The sample selection was built on snowballing
from a core group of identified executives in the biopharmaceutical sector as well as professional
references from identified experts at professional congresses on the topic of innovation and the
use of artificial intelligence in the biopharmaceutical sector. There was no restriction with
respect to geography so long as the respondent was a subject matter expert with relevant
knowledge in drug discovery and development. All invited respondents are currently employed
in the biopharmaceutical sector, as technical and strategic advisors to the biopharmaceutical
sector or as subject matter experts at the intersection of artificial intelligence and the
biopharmaceutical drug discovery and development process.
The survey was distributed in three primary ways; by email invitation through Qualtrics
and a direct link to the survey was provided within the email; through direct communication via
the LinkedIn social networking site, where a direct link was sent to the recipient and through
snowball communication beginning with the researcher’s professional contacts within the
biopharmaceutical industry.
All survey responses have been aggregated as an analytical data point to examine the
proposed hypothesis model in this research and all qualitative answers were captured as additive
descriptors of insight. The responses were kept anonymous to encourage open and complete
responses and all data collected was kept secure and will be destroyed as the research is
competed.
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Measures
The survey instrument is designed to measure the variables proposed in this research,
which are linked to the conceptual framework of the research, the Diffusion of Innovation
Theory. To examine the Diffusion of Innovation variables, biopharmaceutical managers, with
knowledge of the drug discovery and development process were asked a series of questions,
normally 2-4 questions per variable, built on a Likert scale answering model. In addition, 3 openended questions were asked to gain further in-depth understanding of the concepts and value
proposition of artificial intelligence in the drug discovery and development process, from the
viewpoint of the biopharmaceutical manager. Table 4 below, summarizes the alignment of the
survey questions to the variables being examined.
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Table 4. Variable Alignment to Survey Questions
Conceptual Framework

Survey Instrument Measure
Artificial Intelligence represents an advantage in the
process of drug discovery and development.

Perceived Advantage

Using artificial intelligence in drug discovery and
development represents a competitive advantage
compared to other companies.
The use of Artificial Intelligence in drug discovery
and development fits well with my firm or industry
values.

Fit with existing firm values
My firm or industry embraces new technology
platforms as part of our corporate culture.
My firm or industry would accept structural shifts if
efficiencies were gained through the implementation
of artificial intelligence in drug discovery and
development.

I understand the current use and implementation of
artificial intelligence in drug discovery and
development.
The ways in which artificial intelligence are
currently being used in drug discovery and
development are well understood in my
organization.
Ease of understanding
I could explain, in detail the ways in which artificial
intelligence is being used in drug discovery and
development.
The tangible results from innovation with artificial
intelligence in drug discovery and development are
evident.
Results from innovation
The results from the use of artificial intelligence in
drug discovery and development are distinct and
easily separated from other technological advances
Investment in artificial intelligence represents a
sound strategic use of resources.

Management View of AI in DDD

In your view, does executive leadership generally
understand the potential benefits of investment in
Artificial Intelligence within drug discovery and
development?
Within the process of drug discovery and
development, I view artificial intelligence as a
distinct and unique value.
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Management Impact on the Diffusion of
Innovation (AI)

Do you currently make management decisions
regarding investment in drug discovery and
development, which may include budget allocation
for R&D?
How would you rate your level of involvement in the
investment decisions regarding drug discovery and
development?
What is the primary value, in your view, of Artificial
Intelligence specific to the drug discovery and
development process?

Open Ended Questions

Have you observed to date, any direct benefits from
the introduction of AI into the drug discovery and
development process? If yes, please explain.
In your view, will the continued growth of Artificial
Intelligence within the drug discovery and
development process change the scale of resources
(time, money, manpower, etc.) needed to bring new
drugs to market, and if so, what will this change
look like?
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Analysis
The analytical framework was guided by the work of Joseph Hair Jr. et al, whose
examination on multivariate analysis provides a roadmap for which analytics to run for
maximum capture in analyzing multiple variables within a model. (Hair, 2006) Nominal scaling
was applied to the quantitative survey results to make all responses objectively measurable and
for each variable, collinearity was tested to ensure that accurate and distinct measurements for
each variable were achieved. Analytical methodology for the quantitative survey results began
with Cronbach’s Alpha analysis to ensure the construct reliability for each variable in the
proposed model. The statistical results for each variable are provided in the sampling section of
this research.
Reliability was tested on each group of survey questions, making up variable
measurements to ensure the targeted outcome was being evaluated, using Cronbach’s Alpha.
Dimension reduction was performed for each set of survey inputs through Principal
Component Analysis to reduce the total number of relevant inputs into super variables which
most accurately assess each independent and dependent variable.
Each variable in the model was tested for correlation through a Pearson’s r analysis at the
individual variable level. In addition, following the
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Results
As a reminder, the central research question is: Does management view of the value of
artificial intelligence in the process of drug discovery and development impact the level of AI
adoption?
Overall, 44 independent responses were received through the survey instrument. These
respondents represented 10 biopharmaceutical manufacturers invested in drug discovery and
development, as well as biopharmaceutical subject matter experts and strategic advisors and
were all executive level managers with responsibility for operations, finance, strategic
investment and drug discovery and development in varying levels.
Beginning with measures of reliability, all the tested hypotheses variables have shown
reliability using Cronbach’s Alpha as a measurement. Reliability of the individual hypothesis in
the model ranged from moderate to high reliability and are detailed within each variable below.
Independent hypothesis variables were first tested individually for their correlation to the
dependent variable of Management View of AI in Drug Discovery and Development. The model
variables Perceived Advantage and Ease of Understanding proved to be positive and
significantly correlated to the management view of AI in drug discovery and development, using
Pearson’s R as a measurement of correlation. Innovation Fit within existing firm values and
Observable Results showed only moderate and not statistically significant correlation to
Management view of AI in drug discovery and development, again using Pearson’s R as a test of
this correlation.
Subsequently all independent variables were tested as a collected input using multivariate
correlation in relation to the dependent variable, Management View of AI in Drug Discovery,
and Development. The summary of all test and validity measures is outlined in Table 5., below.
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Finally, the correlation between Management View of AI in drug discovery and
development and Innovation Level at the firm is significant and positive in correlation. A
proposed model is displayed below to show the conceptual relationship between variables and
hypothesis.

Innovation (AI)
Perceived Advantage

Innovation (AI) Fit w/
Existing Values

Innovation (AI) Ease
of Understanding

Observable Results
from (AI) Innovation
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Table 5. Measurement and Results

Variable/Item to Measure

Measure and Purpose

Result

Perceived Advantage

Cronbach’s Alpha-Test of
Variable Reliability
Cronbach’s Alpha-Test of
Variable Reliability
Cronbach’s Alpha-Test of
Variable Reliability
Cronbach’s Alpha-Test of
Variable Reliability
Cronbach’s Alpha-Test of
Variable Reliability

.695-Marginally at
accepted threshold
.726-Above accepted
threshold
.707- Above accepted
threshold
.611-Not above
accepted threshold
.735-Above accepted
threshold

Pearson’s r Correlation

.422 with Correlation
Significant at 0.05
Level

Positively and
significantly
correlated

Pearson’s r Correlation

.290 and Not Significant
at 0.05 Level

Positive but not
significantly
correlated

Pearson’s r Correlation

.453 and Correlation
Significant at 0.05
Level

Positively and
significantly
correlated

Pearson’s r Correlation

.139 and Not Significant
at 0.05 Level

Positive but not
significantly
correlated

Pearson’s r Correlation

.377 and Correlation is
Significant at 0.05
Level

Positively and
significantly
correlated

Ease of Understanding
Fit with Existing Firm
Values
Observable Results
Management View Impact
on Firm Adoption
Perceived Advantage
Variable Impact on
Management View
Variable
AI Fit with Firm Values
Variable Impact on
Management View
Variable
Ease of Understanding
Variable Impact on
Management View
Variable
Observable Results
Variable Impact on
Management View
Variable
Management View
Variable Impact on Firm
Innovation Level Variable
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Found to be reliable
measure within
rounding error
Reliable Measure
Reliable Measure
Moderately reliable
Reliable Measure
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H1. The perceived advantage of innovation (AI) impacts management view of that innovation.
This variable did prove to be a reliable measure of the how biopharmaceutical managers
perceived the advantage of using artificial intelligence in the drug discovery and development
process. Perceived advantage is significantly and positively correlated to the management view
of artificial intelligence in drug discovery and development.
Of the managers in the survey, more than one third strongly agreed that artificial
intelligence represents an advantage in the drug discovery and development process, while only
4.8% strongly disagree with the same statement. When asked however, if the use of artificial
intelligence in drug discovery and development represents a competitive advantage, those same
managers strongly agreed only 21% of the time, while 26% responded that they agreed
somewhat. This may indicate that AI in drug discovery and development is seen as a commodity
at this point or that managers do not grasp the benchmark of how well or poorly AI is integrating
into competitive firms.
Hypothesis 1 is upheld as valid in this research.

H2. Innovation fit with the existing values of a firm, will impact management view of the
innovation.
While the instrument for testing innovation fit proved to be reliable, there is little
correlation between Fit with existing firm values and management view of AI in drug discovery
and development. This metric in fact saw the highest level of neutral responses in the form of
neither agree nor disagree statements within the survey instrument at 27.6%. This may indicate
that managers do not understand enough about the adoption of AI to assess the fit within the firm
culture or that the culture would take no notice of innovation adoption in this area. This is
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especially interesting because when the same managers were asked if their firm embraces new
technology platforms without including the element of culture, 55% strongly agree. Perhaps
managers do not associate technology platforms directly with AI in the setting of drug discovery
and development or perhaps there is little nuance in terms of assessing cultural fit through a lens
of technology and/or AI adoption.
Hypothesis 2 is not upheld in this research.

H3. The ease of understanding AI will impact management view of the innovation (AI)
Cronbach’s Alpha shows statistical reliability in the survey instrument for showing Ease
of Understanding as a measure with a score of .726. In addition, Ease of Understanding as an
independent variable showed a significant and positive correlation to Management View of AI in
Drug Discovery and Development. When managers were asked if they understood the ways in
which artificial intelligence was being used in drug discovery and development, fully 75% of
managers agreed or strongly agreed, yet when the question was refined to ask if those same
managers could explain in detail how AI was being applied, only 40% agreed or strongly agreed.
This makes sense as the use of AI is often highly technical and specific in its application, but this
also enforces the condition of a lack of diffusion of this innovation as a key component to
diffusion is the ability to communicate the innovation, its benefits and fit within an organization.
An argument could be made that a lack of true understanding is linked to an ability to diffuse an
innovation.
Hypothesis 3 is upheld in this research.
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H4. Observable results from an innovation (AI) impact management view of the innovation
The survey instrument showed moderate reliability for the variable of Observable Results
from innovation impacting management view of the innovation. Cronbach’s Alpha revealed a
score of .611, not reaching the generally accepted threshold of .7 or greater. In addition, using
Pearson’s r, this variable is not significantly correlated to the management view of AI in drug
discovery and development.
Within this variable measurement, 55% of managers surveyed indicated that they were
either neutral or negative when asked if the tangible results of AI implementation in drug
discovery and development were evident. This is compared with only 30% of respondents
indicating they either agreed or strongly agreed with this statement. This may be because
tangible results of AI implementation are difficult to quantify among the overall result of
bringing new drugs to market. The second question this variable was aimed at clarifying this
result by asking if the results of implementing AI in drug discovery and development are distinct
and easily separated from other technological advances. To this query, 69% of managers were
either neutral or disagreed that it was possible to show distinct and easily separated results from
the implementation of AI, versus only 21% who agreed or strongly agreed that distinct results
were easily separated. This results also seem to support the previous variable findings that there
is often macro understanding of the use of AI without specific knowledge of how AI platforms
are creating value and advantage for the firm or the industry.
Hypothesis 4 is not upheld in this research.
H5. Management view of innovation (AI) impacts the innovation level for the firm.
Cronbach’s Alpha measured a high degree of reliability in the survey instrument to show
management view, yielding a score of .735. Management view is significant and positively
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correlated to level of innovation adoption for the firm. Pearson’s r revealed a statistically
significant score of .377 between the two variables.
Within this variable, 90% of managers in the survey agree or strongly agree that
investment in AI represents a sound strategic use of resources, however we again see a drop in
the level of positive response when the question is refined to ask if the managers see AI in drug
discovery and development as a unique and distinct value, with 70% of respondents agreeing or
strongly agreeing. In addition, 27% of managers were either neutral or somewhat disagreed with
the proposition that AI within drug discovery and development represents a unique and distinct
value. This would appear to reinforce that a macro understanding and acceptance of AI as a
value add is present in the biopharmaceutical sector but that far less is understood about the
specific applications and advantages that may be created by these platforms.
Hypothesis 5 is upheld in this research.

Table 6. Overview of Statistical Measurements Used in Testing
Measurement Tested
Reliability

Method Used
Cronbach’s Alpha

Multicollinearity

Variance Inflation Factor
(VIF)
Correlation between variables Pearson’s r: Linear
Regression: Multivariate
Regression
Dimension Reduction
Principal Component
Analysis
Frequencies and Descriptive
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Descriptive Statistics (SPSS)

Test Applied To
All variable measurements:
Quantitative Survey
All independent and
dependent variables
All independent and
dependent variables
All individual survey
questions to build aggregate
variables
Individual survey responses;
individual variable responses
and inputs
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Discussion
The literature on drug discovery and development and its intersection with the use of
artificial intelligence confirms that AI represents a tremendous opportunity to improve the
efficiency, cost, accuracy and predictability of the drug discovery and development process.
What is also clear is that while implementation is more pronounced in areas such as high
throughput screening (HTS) of chemical compounds and the use of machine and deep learning to
improve clinical testing models, the biopharmaceutical industry overall is in the early stages of
adopting and implementing AI throughout the process of drug discovery and development.
This limited uptake of AI may be the product of several factors including the historically
limited availability of the necessary data sets and chemical and scientific libraries necessary for
research as well as the nature of the technology itself, which is evolving daily. This research
shows however, that one principal factor contributing to the slow uptake of AI in drug discovery
and development may be the value perception of the technology that is held by
biopharmaceutical managers who influence the level of adoption, investment in technology
platforms and firm-level acceptance of AI as a strategic and valuable imperative for the
biopharmaceutical industry. In general, both literature and the survey instrument support the fact
that managers generally see advantage in the implementation of artificial intelligence in the
process of drug discovery and development, however, when drilling down to more specifically
how AI is being applied and what advantages it provides, biopharmaceutical managers do not
seem to have a solid footing for understanding this. There also seems to be a disconnect between
understanding the advantage and value of AI in drug discovery and development and firm level
adoption of this technology. One interesting example to support this came from the survey which
revealed that 61% of managers believe executive leadership at their organization does understand
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the potential benefits of artificial intelligence in drug discovery and development, yet 51% of the
same managers volunteered that the implementation of AI in drug discovery is not a strategic
imperative. This likely indicates that while broad knowledge of AI as a valuable platform exists
at the firm and leadership level, the specific and distinct advantages offered by AI may not be
well enough understood to be discussed as a core strategy.
The results from the quantitative survey also support the position that the perceived
advantage, and the ease of understanding the use of artificial intelligence in drug discovery and
development have a positive and significant impact on the value proposition that managers hold
for this technology. This is supported as well within the Diffusion of Innovation theory which
specifies the importance of understanding and a perceived advantage as factors to diffusing an
innovation throughout a firm. What is equally insightful is that when managers, who generally
agreed that AI in drug discovery represents a perceived advantage were asked if AI presented a
competitive advantage, they did not support this view. So, AI in drug discovery may be seen as
an advantage internally as an efficiency platform or potential cost saver, but it is viewed as a
commodity in terms of advantage versus other biopharmaceutical firms.
Equally interesting is that most managers responding to the survey, indicated that
recognizable and distinct results from the use of artificial intelligence, as well as organizational
fit of using this new technology were not significant or well correlated to the value view held
regarding the use of AI in drug discovery and development. In other words, while these
biopharmaceutical leaders generally agreed that AI represents an advantage, is easy to
understand and is generally seen by executive leadership as an advantage, these managers were
not able to see distinct or unique value adds from the implantation of AI. This suggests again that
there is a macro acceptance of AI within drug discovery as an advantage, but little tangible
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evidence that its application and benefit are widely understood by management. This was further
demonstrated by managers who responded with 90% agreement that investment in AI represents
a sound strategic use of resources, while only 70% agreed that AI in drug discovery and
development represents a unique and distinct advantage.
Also, in support of these findings a very telling insight on its own was the fact that there
was little correlation between the observable results of AI implementation in drug discovery and
the management view of AI, perhaps again, because the specific impact of AI in not well
understood by biopharmaceutical managers beyond a macro understanding that advantage is
gained by implementing AI. In fact, 55% of managers surveyed indicated that they were either
neutral or negative when asked if the tangible results of AI implementation in drug discovery and
development were evident, pointing to the condition that high level understanding and
implementation and acceptance of AI in drug discovery has not reached the level of a core
strategy approach within the industry to date. These findings were paired with survey results
showing 69% of managers were either neutral or disagreed that it was possible to show distinct
and easily separated results from the implementation of AI, versus only 21% who agreed or
strongly agreed that distinct results were easily separated.
To be clear, a minority of responding managers in the survey more clearly articulated
specific benefits to implementing AI in drug discovery, for example one executive manager,
currently serving at a biopharmaceutical firm stated “With platforms like Google's DeepMind,
and then the rise of quantum computing, it may very well mean you need fewer bench scientists
and more computational specialists / AI talent. The new R&D talent won't be scientists but
"bilingual scientists" at the intersection of biology and IT. AI is pushing medicine to be
"programmable" and will essentially move drug discovery from trial and error to an iterative
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process. We can now move from designing a molecule for one specific target to designing a
platform on which many future medicines can be built. Like software upgrades, programmable
medicines make it increasingly possible to improve a given medicine in subsequent generations.
Science essentially becomes engineering.” Despite these minority responses however, the
majority of responding managers were not able to connect specific, unique, or distinct value adds
to the drug discovery process.
In addition, what is clear is that there is a delineation between those leaders and managers
with more technical positions and those with operational positions of leadership. In the openended question section of the survey, every case of detailed explanations and examples of the use
of AI in drug discovery was sourced from those managers and leaders who self-identified as
being technical, clinical, or scientific leaders in their organization, opposed to those who
identified as operational, executives and leaders. A larger sample size, with greater detail and
delineation of roles and responsibilities may be appropriate in future research to bifurcate the
responses clearly along the lines of responsibility and organizational roles.
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Conclusion
Managers and leaders in biopharmaceutical companies face an uphill battle every day in
allocating limited resources, making strategic investment decisions in the realm of research and
development, and implementing new technologies for improved organizational and outcome
efficiency, all while facing the public debate over drug prices. Brining new medications to
market remains a critical concern for these leaders, as it represents not only the avenue to
continued success for the industry, but the best path for brining critically needed medications to
patients.
Artificial intelligence offers great potential to increase the efficiency and predictability of
results in the drug discovery and development process along with potential to shorten the current
10 plus year average time to bring new medications to market. Beyond this, it is feasible that AI,
by increasing efficiency, complimenting human scientific work, combing through vast millions
of potential chemical compounds, and modeling the likely outcome will lower the cost of
bringing new medications to market from the current figures of more than $2Billion. This has
great potential impact on the price of medications for patients and society.
To gain the full potential of AI in this setting and to ensure that these technology
platforms are maximized, it is crucial that biopharmaceutical managers understand the platforms,
their true value, and the need to approach these advancing platforms as a strategic imperative to
bringing new drugs to market. This research and the literature that supports it, suggests that
currently the industry is in the early stages of implementation of AI and that biopharmaceutical
managers have only a rudimentary understanding of the applications and benefits of AI in drug
discovery and development. Given that these managers make decisions on the investment of
resources, it is imperative that they gain a greater understanding of the potential value,
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competitive advantage, and added value to their organizations by more fully adopting and
diffusing AI across the firm and especially in targeted function areas such as drug discovery and
development.
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Recommendations
There are steps that biopharmaceutical firms and their executive leadership may take to
improve the understanding, diffusion and use of artificial intelligence related to drug discovery
and development. Outlined below are a few simple suggestions that are supported by the findings
of the literature review and the survey responses from this research.
•

Integrate clinical and R&D position representatives into executive leadership
meetings and strategic planning meetings to add a more complete understanding
of the value being offered and added by the implantation of artificial intelligence
in the setting of drug discovery and development.

•

Task clinical and research and development subject matter experts with providing
not only tangible results created by the implementation of artificial intelligence
but also of providing a historic understanding of the efficiencies gained through
the implantation of AI in drug discovery to the executive leaders, so that gains are
more evident over time.

•

Task clinical and research and development teams with providing benchmarks of
the use of AI from other competitive firms in the industry; this may bring both
efficiency in terms of where and when to invest and provide a competitive
advantage if technology can be leveraged to surpass competition.

•

Make the implementation of AI more palatable by discussing gains and progress
in town hall and open settings to assist all employees at the firm in diffusing and
accepting the advantages being gained. This may provide an additional benefit of
encouraging career mobility into AI and drug discovery from qualified internal
resources
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Limitations and Future Research
Limitations of this research stem from the sample size, as biopharmaceutical companies
vary in their level of adoption with artificial intelligence, their risk profile and their strategic
commitment to research and development. A larger sample population, combined with in-depth
interviews in addition to a survey instrument may yield greater insight into the approach taken by
biopharmaceutical managers with respect to AI in drug discovery and development. In fact, an
analytical preference would be to use causal modeling to more directly demonstrate and examine
the relationships between variables and outcomes, however, the sample size in this research
made such analysis problematic, but certainly presents an opportunity for future research.
There is an opportunity for more nuanced research into the specific applications of
artificial intelligence in various sections of the drug discovery and development process, where
this research was a broad stroke in the application of AI in the general process and how it is
being applied currently. One area in which this can be accomplished is by approaching
biopharmaceutical managers in a bifurcated manner, so that those leaders with a more technical
leadership position in research and development can be evaluated compared to those leaders in
operational and executive positions. This approach may bring value in illuminating elements of
the disconnect between the macro understanding of AI and its use in drug discovery and an indepth knowledge of the use and application of AI in drug discovery.
One area that may yield more precise results for future research is to gain access to real
world expenditures by several biopharmaceutical companies in the research and development
stage and compare this to cost estimates and time estimates for bringing new drugs to market. In
addition, this may yield valuable insights into a more precise measure of how AI is being used in
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this setting and how the application and adoption of AI has changed over time within a given set
of organizations.
Finally, although some recent literature does address the topic in general terms, it is
equally important to analyze and research those areas in which artificial intelligence has been
applied and has not been successful. Since the use of AI is still relatively early in its lifecycle,
this was not possible until recently, but understanding where platforms are not adding value may
be equal in importance to understanding and examining where they do add value.
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Contribution
Through an empirical examination of the real-world costs and resource demands of drug
discovery and development, alongside the growing use of artificial intelligence, this research
may help to inform the biopharmaceutical sector in developing meaningful, long-term strategy
regarding the balance between the implementation of new technology, in the form of artificial
intelligence and resource allocation in the risky and lengthy process of drug discovery and
development. The goal is to add to the research providing an objective background for more
accurate forecasting of the likelihood of success or failure in drug discovery and development
through the innovations offered by artificial intelligence, at least in the limited definitions with
which it is applied in this research.
The application of the lens of the Diffusion of Innovation Theory will provide a grounded
basis for management on the added value of being early or late-stage adopters of this technology
and will help to inform a more thorough communication strategy plan for firms that wish or need
to embrace the introduction of these innovations. In addition, this research has the aspiration of
informing managers in the biopharmaceutical sector on the importance of gaining high level
understanding of what AI can bring to the table in the context of drug discovery and
development and the importance of communicating these advantages as a strategic platform to
propel more efficient and less costly growth in new medications coming to market.
On a larger scale, it is the ambition of to add to the literature and evidence on a more
holistic approach to understanding and discussing medication prices and costs, through the lens
of research and develop sunk costs. More specifically, this research has the aspirational goal of
providing more transparency into the market forces, as well as the costs and time associated with
the development of new medications, to provide the basis for a more complete discussion and
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consideration of a primary driver of medication cost, namely, the discovery and development of
new medications.
Ultimately, the cost of discovering and developing new medications is becoming
prohibitive and discouraging many companies in the life science sector from investing in
research and development. Through insight, analysis and evidence, this research will better
prepare biopharmaceutical companies to undertake drug discovery and development.
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Engaged Scholarship Approach
One reason this area of research is important to me is that I have been employed in the
biopharmaceutical sector for several years. My approach is to conduct evidence-based research
that can be applied both academically and practically to address and solve real world current
issues. The drug discovery and development process offers myriad research opportunities both as
a business practice and a scientific endeavor and my aspiration is to see more evidence and
structure used to evaluate the drug discovery and development process, if for no other reason,
than to bring a more objective lens to discussions about drug prices, actual costs and the level of
resource investment that is needed to discover critical new medications and cure for illness.
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Appendices
Appendix A
Qualtrics Survey Instrument
Please provide your Name and Job Title
Last Name
Fist Name
Job Title
Organization Name

Responsibility Level (Director, VP etc.)
What is the primary classification for your role in leadership?
• Operational/Commercial
• Clinical/Technical
• Subject Matter Expert
• Academic/Consultant
• Other
Do you currently make management decisions regarding investment in drug discovery and development, which may
include budget allocation for R&D?
• No
• Sometimes
• Yes
How would you rate your level of involvement in the investment decisions regarding drug discovery and
development?
Not at all involved
Extremely Involve
0
1
2
3
4
5
6
7
8
In your organization or professional experience, which department within the firm is primarily responsible for
investment decisions and/or technology implementation for drug discovery and development?
• Clinical/Medical
• Operational Leadership
• Executive Leadership
• Other-Please Specify
To what extent do you agree with the following statement? Artificial Intelligence represents an advantage in the
process of drug discovery and development.
• Strongly Disagree
• Disagree
• Neither agree nor disagree
• Somewhat agree
• Strongly agree
Artificial intelligence in drug discovery and development represents a competitive advantage compared to other
companies.
• Strongly Disagree
• Somewhat disagree
• Neither agree nor disagree
• Somewhat agree
• Strongly agree
It is possible for a biopharmaceutical company, invested in drug development and discovery to be competitive
without implementing or incorporating artificial intelligence into the process
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• Strongly disagree
• Somewhat disagree
• Neither agree nor disagree
• Somewhat agree
• Strongly agree
The use of Artificial Intelligence in drug discovery and development fits well with my firm or industry values.
• Stongly Disagree
• Disagree
• Neither agree nor disagree
• Somewhat agree
• Strongly agree
My firm or industry embraces new technology platforms as part of our corporate culture.
• Strongly disagree
• Somewhat disagree
• Neither agree nor disagree
• Somewhat agree
• Strongly agree
My firm or industry would accept structural shifts if efficiencies were gained through the implementation of
artificial intelligence in drug discovery and development.
• Strongly disagree
• Somewhat disagree
• Neither agree nor disagree
• Somewhat agree
• Strongly agree
I understand the current use and implementation of artificial intelligence in drug discovery and development.
• Strongly disagree
• Somewhat disagree
• Neither agree nor disagree
• Somewhat agree
• Strongly agree
The ways in which artificial intelligence are currently being used in drug discovery and development are well
understood in my organization.
• Strongly disagree
• Somewhat disagree
• Neither agree nor disagree
• Somewhat agree
• Strongly agree
I could explain, in detail the ways in which artificial intelligence is being used in drug discovery and development.
• Strongly disagree
• Somewhat disagree
• Neither agree nor disagree
• Somewhat agree
• Strongly agree
I know that artificial intelligence is being used in drug discovery and development, but I do not understand how it is
being used.
• Strongly disagree
• Somewhat disagree
• Neither agree nor disagree
• Somewhat agree
• Strongly agree
The tangible results from innovation with artificial intelligence in drug discovery and development are evident.
• Strongly disagree
• Somewhat disagree
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• Neither agree nor disagree
• Somewhat agree
• Strongly agree
The results from the use of artificial intelligence in drug discovery and development are distinct and easily separated
from other technological advances.
• Strongly disagree
• Somewhat disagree
• Neither agree nor disagree
• Somewhat agree
• Strongly agree
Investment in artificial intelligence represents a sound strategic use of resources.
• Strongly disagree
• Somewhat disagree
• Neither agree nor disagree
• Somewhat agree
• Strongly agree
In your view, does executive leadership generally understand the potential benefits of investment in Artificial
Intelligence within drug discovery and development?
• Yes
• No
At your organization, is the implementation of Artificial Intelligence for drug discovery and development, discussed
as a strategic imperative?
• Yes
• No
Within the process of drug discovery and development, I view artificial intelligence as a distinct and unique value.
• Strongly disagree
• Somewhat disagree
• Neither agree nor disagree
• Somewhat agree
• Strongly agree
What is the primary value, in your view, of Artificial Intelligence specific to the drug discovery and development
process?
Have you observed, to date, any direct benefits from the introduction of AI into the drug discovery and development
process, if yes, please explain?
In your view, will the continued growth of Artificial Intelligence within the drug discovery and development process
change the scale of resources (time, money, manpower, etc.) needed to bring new drugs to market, and if so, what
will this change look like?

Appendix B
Table x Machine Learning Concepts Defined
Concepts

Definition

Supervised learning predicts labels or classes on future data based on past data that
Supervised,
includes labels/classes. Unsupervised learning identifies structure, usually clusters,
unsupervised, and semiamong unlabeled data. Semi-supervised learning first performs unsupervised learning,
supervised learning
and humans label structures found from unsupervised learning.
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Concepts

Definition

Classification and
regression

Both are supervised learning methods. Classification predicts discreet categories such as
normal versus diseased while regression predicts real-valued outputs such as response to
therapy.

Ensemble learning

Ensemble methods build many models and use the average of all models to produce
predictions. Common ensemble approaches include random forests, gradient-boosting,
and stacking/meta-ensembles.

Deep learning

Multi-layer artificial neural networks that can learn complex non-linear functions.
Very useful for unstructured data such as images, speech, or text but typically do
not provide insights into the aspects of the data that are driving the functions.

Dimensionality
reduction

Reduces the number of attributes or features of a dataset by selecting important features
or combining features to capture variance in a dataset. Often used to improve
performance of machine learning models and to aid visualization.

Federated learning

Approaches for incrementally learning from data distributed in multiple locations and
which cannot be combined into a single dataset. Federated learning is useful when data
are in multiple clinical systems or when learning from sensitive personal data.

(Source: Goecks, 2021How Machine Learning Will Transform Biomedicine)
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